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Abstract. Neuroblastoma (NB) has a poor prognosis when 
in advanced stages, highlighting the need for new therapeutic 
options. The human immunodeficiency virus (HIV) protease 
inhibitor saquinavir is active in vitro against chronic myeloid 
leukaemia cells, in synergy with the tyrosine kinase inhibitor 
imatinib. Here, we evaluated the effects of saquinavir, 
alone or in association with imatinib, on cell proliferation 
(count of viable cells after trypan blue exclusion), apoptosis 
(Annexin V binding) and invasion (through a transwell 
membrane coated with Matrigel) in SJ-N-KP, IMR5, AF-8, 
SK-N-SH and SK-N-BE NB lines, all expressing c-kit and 
PDGF-R (determined by flow cytometry). Saquinavir showed 
a dose-dependent anti-proliferative and anti-invasive activity 
on NB lines, increased by the association with imatinib when 
the two drugs were utilized at clinically attainable concentra-
tions. The same low saquinavir concentrations inhibited in 
NB cells the nuclear activation of NF-κB (Western immuno-
blotting for nuclear NF-κB p50 and p65). Saquinavir at high 
concentrations also exerted a pro-apoptotic activity on NB 
lines, significantly increased by the association with imatinib. 
In conclusion, saquinavir and imatinib are both drugs utilized 
for long-term therapies, with good oral bioavailability and a 
well-known toxicity profile. The anti-NB activity of saqui-
navir and of its association with imatinib suggests a potential 
usefulness in the treatment of NB, particularly for remission 
maintenance.
Introduction
Human immunodeficiency virus (HIV) protease inhibitors 
(PIs) are widely utilized antiretroviral drugs (1) which also 
show anti-cancer activity. Since the initial observation that 
they promote regression of Kaposi sarcoma by inhibiting 
angiogenesis (2), their direct antitumour effects have been 
documented on various tumour cell lines, such as human 
prostate carcinoma, glioblastoma, leukaemia, non-small cell 
lung cancer and melanoma (3-6). This antitumour activity has 
been related to impaired proteasome function, inhibition of 
cyclin-dependent kinase (CDK) 2 and a decrease in growth 
factor-induced or endogenous Akt-driven signalling (6-10). 
In other experimental models, PIs at therapeutic dosages have 
been shown to affect the proteolytic activity of purified human 
proteasomes and to prevent NF-κB activation (11). According 
to the above reports, we previously demonstrated that the PI 
saquinavir exerts inhibitory and pro-apoptotic activity on 
chronic myeloid leukaemia (CML) cells, in synergy with 
imatinib, with a stronger effect on the imatinib-resistant CML 
cell lines (12). These saquinavir-mediated effects were asso-
ciated with a reduced NF-κB nuclear translocation. Imatinib, 
also defined as STI571, was initially described to inhibit 
the in vitro growth of Bcr-Abl-positive CML cells through 
selective inhibition of the Abl tyrosine kinase, and then 
proved to exert inhibitory activity on tyrosine kinase recep-
tors such as c-kit and platelet-derived growth factor receptor 
(PDGF-R) (13).
Neuroblastoma (NB) is the third most common paediatric 
cancer. It is an embryonic cancer derived from the peripheral 
sympathetic nervous system with a heterogeneous clinical 
course ranging from spontaneous regression to very aggres-
sive forms. In advanced disease stages, NB has, in spite of 
aggressive multimodal therapy (14), a poor prognosis, with 
a long-term survival of <40% in high risk patients, thus 
highlighting the need for new therapeutic options (15-19). A 
number of observations indicate that c-kit, PDGFR and their 
ligands play a substantial role in the survival and prolifera-
tion of NB cells (20-24). Imatinib is active against NB cells 
in vitro and in xenografts (24-27), but it shows little or no 
activity as a single agent in children with relapsed or refrac-
tory NB (28).
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The aim of the present study was to investigate the effects 
of saquinavir alone or in combination with imatinib in NB cell 
lines, in order to evaluate a possible additive antitumor activity 
of the two drugs.
Materials and methods
Saquinavir and imatinib stock solutions. Saquinavir (Roche, 
UK) and Imatinib (STI571; Novartis Pharmaceuticals, Basel, 
Switzerland), were solubilized in 100% dimethyl sulfoxide 
(DMSO) at final concentrations of 40 and 1 mM, respectively, 
and used as the stock solution for all experiments.
Cell cultures. The NB cell lines SJ-N-KP, IMR5, AF-8, SK-N-
SH, SK-N-BE (29-31) were maintained in monolayer cultures 
in RPMI-1640 medium supplemented with 10 or 1% fetal calf 
serum (FCS), 2 mM L-glutamine, 100 µg/ml streptomycin and 
100 IU/ml penicillin at 37˚C in a 5% CO2 humidified atmosphere.
Flow cytometry for PDGF-Rβ. SJ-N-KP, IMR5, AF-8, 
SK-N-SH, SK-N-BE cells (5x105) were incubated with an 
anti-PDGF-Rβ chain monoclonal antibody (R&D Systems, 
Minneapolis MN, USA) for 20 min at 4˚C. After washing, 
the cells were incubated with PE-conjugated goat anti-mouse 
secondary antibody (BD Pharmingen, San Diego, CA, USA) 
for 30 min and then analyzed by a BD FACSCanto (BD 
Pharmingen). The osteosarcoma cell line SJSA-1 (obtained 
from the American Type Culture Collection) was utilized as 
a positive control.
Cell proliferation assays. The exponentially growing SJ-N-
KP, IMR5, AF-8, SK-N-SH, SK-N-BE cell lines were cultured 
in the presence or absence of saquinavir from 0.1 up to 40 µM, 
imatinib from 0.001 to 50 µM or the association of saquinavir 
5 µM with increasing imatinib concentrations for 24, 48 or 
72 h. Following exposure to the drugs or DMSO (control), 
the cells were trypsinized, harvested and stained with trypan 
blue for their viability evaluation. Cellular proliferation was 
determined by quantifying viable cells manually using a 
haemocytometer. Inhibiting concentrations of 50% (IC50) 
were calculated by nonlinear regression analysis using the 
SPSS 11.5 software package (SPSS, Inc., Chicago, IL, USA). 
Experiments were performed in triplicate.
Because there is a reported interference of imatinib with 
the most commonly utilized MTT test which can lead to erro-
neous results (32), this technique was avoided.
Apoptosis assays. Following 24, 48 and 72 h exposure of 
SJ-N-KP, IMR5, AF-8, SK-N-SH, SK-N-BE cells to various 
concentrations (Fig. 3) of saquinavir, imatinib, imatinib 
plus saquinavir 5 µM or DMSO (control) in the presence 
of 1 or 10% FCS, the cells were trypsinized and harvested. 
Apoptosis was evaluated by two colour-flow cytometry, 
using Annexin V-FITC conjugates (apoptosis detection kit, 
R&D Systems), according to the manufacturer's instruc-
tions, with an EPICS XL2 Coulter flow cytometer (Beckman 
Coulter, Inc., Brea, CA, USA). This method evaluates cells 
in early (Annexin V+/propidium iodide-) and late apoptosis 
(Annexin V+/propidium iodide+). Experiments were performed 
in triplicate.
Invasion assays. Cell migration was evaluated in SJ-N-KP, 
IMR5, AF-8, SK-N-SH, SK-N-BE cell lines using 24-well 
transwell plates (6.5-mm diameter) with an 8-µm pore size 
polycarbonate membrane (Corning Costar, MA, USA) coated 
with Matrigel (BD Pharmingen) 1.25 µg/µl. The lower compart-
ment was filled with 600 µl of IMDM containing 10% FCS 
as a chemoattractant. NB cells (2x104) resuspended in 100 µl 
of IMDM containing 1% FCS in the presence of saquinavir 5, 
10, 20 µM, imatinib 0.01 µM alone or imatinib 0.01 µM plus 
saquinavir 5 µM were added into the upper well and incubated 
at 37˚C. After 24 h incubation, the cells on the upper side of the 
membrane were removed with a cotton swab and the cells on the 
lower side of the membrane were fixed and stained with crystal 
violet. The cells on the entire lower surface of the membrane, 
visualized with an inverted microscope, were counted in 5 fields 
under a x400 magnification. The experiments were carried out 
in triplicate.
Preparation of nuclear extracts. NB cells treated with or without 
5 µM saquinavir for 16 h were stimulated with PMA (phorbol 
11-myristate-12-acetate, Sigma-Aldrich, St. Louis, MO, USA) 
10 ng/ml and calcium ionophore (Sigma-Aldrich) 500 ng/ml for 
15 min. After incubation, cells were washed twice with ice-cold 
phosphate-buffered saline. Pellets were resuspended in buffer A 
(HEPES 10 mM pH 7.9, KCl 10 mM, PMSF 1 mM, DTT 1 mM) 
and cells were homogenized using insulin syringes. After 45 min 
incubation at 4˚C samples were centrifuged at 12,000 rpm for 
10 min. Nuclei were extracted in buffer C (HEPES 20 mM pH 
7.8, MgCl2 1.5 mM, NaCl 420 mM, EDTA 0.2 mM, PMSF 
1 mM, DTT 1 mM, and 25% glycerol) for 30 min on ice, then 
cleared by centrifugation (12,000 rpm for 30 min at 4˚C). Protein 
concentration was determined by the Micro BCA protein assay 
reagent kit (Pierce Chemical, Rockford, IL, USA), following 
the manufacturer's instructions.
Western blot analysis. Samples containing equal amounts of 
protein (20 µg) were resolved on 11% SDS-polyacrylamide 
gels (SDS-PAGE). Resolved proteins were electrotransferred 
onto PVDF membrane, blocked overnight with 5% w/v BSA 
(Sigma-Aldrich) in TBS (Tris 20 mM pH 7.6, NaCl 140 mM) 
containing 0.1% Tween-20 (blocking solution) and probed 
with primary antibodies anti-p65 and anti-p50 (Santa Cruz 
Biotechnology, Inc., Heidelberg, Germany). Immunoreactive 
bands were detected by ECL. Blots were stripped (glycine 
200 mM, SDS 0.1%, Tween 1% pH 2.2) and reprobed with 
anti SP-1 (Santa Cruz Biotechnology) and detected by ECL. 
Relative band intensities were quantified using Quantity one 
image analysis software (Bio-Rad, CA, USA).
Statistical analysis. Drug concentrations causing a 50% 
inhibition of cellular growth (IC50) were calculated by 
nonlinear regression analysis using the SPSS 11.5 software 
package (SPSS, Inc.). Student's t-tests were used to analyse 
the drug effects on cell proliferation, apoptosis and migration. 
P-values <0.05 were considered statistically significant.
Results
NB cell lines express PDGF-Rβ. Flow cytometry demonstrated 
in SJ-N-KP, IMR5, AF-8, SK-N-SH and SK-N-BE cell lines the 
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expression of membrane PDGF-Rβ at comparable levels (Fig. 1). 
The expression of c-kit in the same lines has been previously 
described by our group (22). PDGF-Rβ and c-kit expression 
provide the rationale for the use of imatinib in our study.
Saquinavir alone and in combination with imatinib inhibits 
NB cell line proliferation. Proliferation assays were carried out 
on SJ-N-KP, IMR5, AF-8, SK-N-SH and SK-N-BE cell lines 
exposed for 24, 48 or 72 h to saquinavir or imatinib or the two 
drugs in combination. As single agent saquinavir demonstrated 
a concentration-dependent antiproliferative effect. The associa-
tion of saquinavir 5 µM with various concentrations of imatinib 
caused a significant increase of the imatinib antiproliferative 
activity (considering all cell lines taken together: saquinavir 
5 µM plus imatinib from 0.001 to 10 µM vs. imatinib alone at 
the same concentrations; P<0.01 after 24, 48, 72 h exposure). 
Proliferation assay results and saquinavir IC50 values are shown 
in Fig. 2 and Table I).
Saquinavir alone and in combination with imatinib inhibits 
NB cell invasion through the matrigel matrix. Cell invasion 
assays showed a significant inhibitory effect of saquinavir 
at 5, 10 or 20 µM on cell invasion in SJ-N-KP, IMR5, AF-8, 
SK-N-SH and SK-N-BE cell lines (P<0.0001 vs. control, 
RPMI-1640 plus DMSO) (Table II). Imatinib alone at 0.01 µM 
also inhibited cell migration. The association of imatinib 
0.01 µM with saquinavir 5 µM significantly increased the anti-
invasive activity of the single compounds (saquinavir 5 µM 
Figure 1. SJ-N-KP, IMR5, AF-8, SK-N-SH and SK-N-BE neuroblastoma cell lines express membrane PDGF-Rβ. Flow cytometric analysis was performed by an 
anti-PDGF-Rβ chain monoclonal antibody on cells cultured in RPMI-1640 plus 10% FCS. The osteosarcoma cell line SJSA-1 was utilised as a positive control.
Table I. IC50 of saquinavir and imatinib in NB cell lines.
 24 h 48 h 72 h
 ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------
 Saq Im Saq + Im Saq Im Saq + Im Saq Im Saq + Im
SJ-N-KP 6.96 2.01 0.02 3.17 2.70 0.27 3.80 1.85 0.34
IMR5 6.91 4.01 0.07 3.96 2.14 0.26 3.62 1.36 0.29
AF-8 6.56 4.54 0.63 3.72 1.07 0.08 4.44 0.99 0.08
SK-N-SH 6.54 1.79 0.10 3.33 0.63 0.02 2.49 0.76 0.02
SK-N-BE 4.78 2.63 0.41 4.73 1.27 0.18 3.67 0.98 0.03
IC50 (expressed in µM, calculated by non-linear regression analysis) of saquinavir (Saq), imatinib alone (Im) and imatinib in association with 
saquinavir 5 µM (Im + Saq) in SJ-N-KP, IMR5, AF-8, SK-N-SH and SK-N-BE cell lines.
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Figure 2. Saquinavir, imatinib and their combination inhibit neuroblastoma SJ-N-KP, IMR5, AF-8, SK-N-SH and SK-N-BE cell line proliferation in a dose-
dependent manner. The figure shows the percentage of inhibition of cell proliferation compared to DMSO (drug vehicle) after 72 h exposure to the drugs alone 
or in combination. Data are the mean ± SD of three independent experiments and are expressed as % of inhibition in treated cells. Statistical significance of 
the combination of saquinavir 5 µM with various concentrations of imatinib compared to imatinib alone, *P<0.01.
Table II. Inhibition of NB cell invasion in the presence of saquinavir and imatinib.
 SJ-N-KP IMR5 AF-8 SK-N-SH SK-N-BE
 (%) (%) (%) (%) (%)
5 µM Saq 39±8.5 48±4.9 35±12.0 33±7.1 33±9.2
10 µM Saq 46±9.9 59±6.4 55±0.2 46±0.5 55±11.3
20 µM Saq 67±4.9 72±15.5 71±7.1 69±12.7 75±8.5
0.01 µM Im 54±9.9 52±8.5 35±1.0 45±7.1 31±16
0.01 µM Im + 5 µM Saq 67±9.2 66±11.3 63±12.0 56±12.7 65±3.5
Evaluation of cell invasion through transwell plates with 8-µm pore size polycarbonate membrane in SJ-N-KP, IMR5, AF-8, SK-N-SH, 
SK-N-BE cell lines. Data are expressed as percentages of inhibition of migration compared to the control after 24 h-exposure to saquinavir 
alone at various concentrations, imatinib 0.01 µM or saquinavir 5 µM plus imatinib 0.01 µM. Values are the mean ± standard deviation of 
three independent experiments. The association of imatinib 0.01 µM with saquinavir 5 µM significantly increased the anti-migratory activity 
of saquinavir 5 µM alone (P<0.0001). Saq, saquinavir; Im, imatinib.
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plus imatinib 0.01 µM vs. saquinavir 5 µM alone P<0.001; 
saquinavir 5 µM plus imatinib 0.01 µM vs. imatinib 0.01 µM 
alone P<0.001).
Saquinavir exerts a pro-apoptotic activity on NB cell lines. 
In cells cultured in the presence of 10% FCS, a significant 
saquinavir pro-apoptotic activity was observed only at 
concentrations of 20 µM or higher (data not shown). In 
SJ-N-KP, IMR5, AF-8, SK-N-SH, SK-N-BE cells cultured 
in the presence of 1% FCS, saquinavir exhibited a significant 
concentration and time-dependent pro-apoptotic activity also 
at lower concentrations (10 and 15 µM; P<0.01) (Fig. 3). We 
did not observe a significant difference in the percentage of 
apoptotic cells between the control experiments carried-out in 
the presence of 1% FCS and the control experiments carried-
out in the presence of 10% FCS (data not shown), ruling out 
a possible pro-apoptotic effect of low concentrations of FCS. 
Imatinib at concentrations of 1 and 5 µM caused a negligible 
pro-apoptotic effect on the SJ-N-KP, IMR5, AF-8, SK-N-SH, 
SK-N-BE cell lines, whereas the association with imatinib 
significantly increased the pro-apoptotic activity of saquinavir 
(saquinavir 10 µM in combination with imatinib 5 µM vs. 
saquinavir 10 µM: P<0.05 after 24 h; P<0.001 after 48 h; 
P<0.001 after 72 h).
Saquinavir inhibits nuclear translocation of NF-κB in NB 
cells. Western blotting experiments demonstrated a significant 
reduction of nuclear p65 and p50 in PMA-stimulated NB cells 
after exposure to saquinavir 5 µM. Fig. 4 shows a representa-
tive analysis in the SJ-N-KP cell line.
Discussion
The direct anti-cancer activity of some HIV PIs has been 
previously described (2-6). In the present study a significant dose-
dependent anti-proliferative effect of saquinavir was observed in 
Figure 3. Saquinavir exerts a pro-apoptotic activity on neuroblastoma SJ-N-KP, IMR5, AF-8, SK-N-SH and SK-N-BE cell lines in a dose-dependent manner. 
The figure shows the percentage of apoptotic cells after exposure to saquinavir alone (Saq), imatinib alone (Im) or the combination of various concentrations 
of saquinavir and imatinib. Cultures were carried out for 24, 48, 72 h in the presence of 1% FCS. The association with imatinib significantly increased the 
pro-apoptotic activity of saquinavir (saquinavir 10 µM in combination with imatinib 5 µM vs. saquinavir 10 µM: P<0.05 after 24 h, P<0.001 after 48 h, P<0.001 
after 72 h). The data express the mean percentage ± SD of three independent experiments.
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NB cell lines. It is worth noting that the IC50 determined in the 
present study was about 1 log lower than in the leukaemic K562 
line (12).
Imatinib, a selective inhibitor of the tyrosine kinase activity 
of c-kit and PDGF-R, is active in vitro against NB cell lines 
(24-27). However, in spite of the pivotal role played by PDGF-R 
and c-kit in promoting cell proliferation and migration and 
in inhibiting apoptosis in NB cell lines (20-24), imatinib has 
shown little or no activity as a single agent in children with 
relapsed or refractory NB (28). The observation that imatinib 
is more effective in preventing the cell proliferation of CML 
lines when in combination with saquinavir (12) prompted us 
to investigate the effects of the association of saquinavir plus 
imatinib on the five NB cell lines, all expressing c-kit and 
PDGF-R. In the present study the association of saquinavir and 
imatinib showed an additive anti-proliferative activity at clini-
cally attainable concentrations (33,34) of both compounds.
Saquinavir also exerted an anti-invasive activity on NB 
cells. This is in line with Sgadari et al (2) that PIs block Kaposi 
sarcoma cell invasion. Vitali et al (35) previously described an 
anti-migratory activity of imatinib in NB. Here, we demon-
strated a significant increase of the anti-invasive activity 
of imatinib when associated with saquinavir at therapeutic 
concentrations, suggesting an anti-metastatic effect that might 
have a significant impact on the outcome of NB patients.
In the presence of 10% FCS, saquinavir exerted a signifi-
cant pro-apoptotic activity on NB cell lines at concentrations 
of 20 µM or higher. However, in the cultures carried out in 
the presence of 1% FCS, saquinavir exhibited a significant 
pro-apoptotic activity at lower and clinically attainable 
concentrations, while low concentrations of FCS had not 
per se a pro-apoptotic activity as shown in control experi-
ments. This might be explained by an anti-apoptotic activity 
of high concentrations of serum, as demonstrated in other 
experimental models (36). Imatinib alone had a negligible 
pro-apoptotic effect on NB cell lines, whereas the association 
with imatinib significantly increased the pro-apoptotic activity 
of saquinavir.
Altogether, our data suggest that, in NB cell lines, the anti-
proliferative and anti-invasive activity of saquinavir, observed 
in the presence of 10% FCS, is prominent compared to its 
pro-apoptotic activity. Since some NB cell lines in the study 
were reported to be MYCN-unamplified/low-expressed (37) 
and some MYCN-amplified/overexpressed (IMR5) (38,39), 
the biological effects of saquinavir and of its association with 
imatinib on NB cell lines seem independent from MYCN 
amplification.
Pajonk et al (6) evidenced that saquinavir inhibits NF-κB 
activation in prostate carcinoma cells. Here we show that low 
saquinavir concentrations inhibit NF-κB p50 and p65 activa-
tion in NB cells. The ubiquitin-proteasome pathway plays a 
key role in the activation of NF-κB and in the degradation of 
its inhibitor Iκ-B. HIV PIs at therapeutic concentrations block 
proteasome activities (11) and thus may impair a large array of 
biological activities, such as cell-cycle progression, angiogen-
esis, and activation of transcriptional factors. The inhibitory 
effects of saquinavir on proteasome functions and NF-κB 
activation may account, at least partially, for its antitumoral 
properties.
In conclusion, saquinavir is a drug utilized in the long-
term treatment of HIV seropositive patients, with good oral 
bioavailability and a well known toxicity profile. Its anti-
proliferative and anti-invasive effects on NB cell lines at 
therapeutic concentrations suggest a potential usefulness for 
the treatment of NB, particularly for remission maintenance. 
The additive activity of low concentrations of saquinavir and 
imatinib seems of particular interest. Targeted animal studies 
are warranted.
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